NovImmune Raises $20.8M Series B Round

Swiss drug discovery and development company NovImmune has raised 20 million Swiss francs ($20.8 million) in Series B financing. BZ Bank Aktiengesellschaft led the round. The new financing will help the company bolster its balance sheet and develop new partnerships, the company said.

North AmericaUSBriefs